

## **Effectiveness of electronic drug monitoring feedback to increase adherence in RA-patients initiating a biological DMARD – a randomised clinical trial**

### Supplementary material

#### *Questions for MIT*

##### **Explorative questions**

- There are many reasons to use medications in another way compared to what was prescribed. How would you describe it for your situation?
- How would you like to do it?
- What would help you with that?

##### *Deeper exploration*

- Do you ever worry about your medication use?
- What have you been told about your medication use?
- What can the medication do for you?
- How does the medication use fit into your life?

##### **Possible solutions**

##### *Related to concerns about medication*

- Explanations about the medication. Use motivational interviewing (listening, silence etc)

##### *Cognitive abilities:*

- Use recall promoting techniques (repeat, categorize, summarize, emphasize)
- Promote patient participation
- Explore information sources of the patient

##### *Related to necessities*


- Give information and advise
- Use recall promoting techniques (repeat, categorize, summarize, emphasize)
- Promote patient participation

##### *Related to daily living*


- Ask about experienced barriers on integrating medication use in daily living
- Give advice and information about integrating medication use in daily living.
- Promote patient participation

##### **Summarize and complete**


- All medications were taken at the right date and time → give compliments and encourage to continue this way.
- Less than 100% but more than 80% at the right date and time → Mention this, explore reasons and give compliments on the right 'periods'
- Less than 80% → mention this, explore reasons
- Large variety → mention this, explore reasons. Emphasize necessity of correct medication use.
- Summarize, (let the patient) set goals for the next period.



**Fig S1.** Flowchart of study enrolment and loss to follow-up.



**Figure S2.** Kaplan-Meier plot of the cumulative probability of achieving remission for (bDMARD starting) patients in the intervention and control group. Each step in the curve represents remission, defined as DAS28-ESR < 2.6.



**Figure S3.** MEMS scores for the feedback group: correct dosing decreased from 92.6% (after 3 months) to 90.5% (after 12 months). Non Monitored Periods were noted and corrected for.